Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 8%
Hold 67%
Sell 25%
Strong Sell 0%

Bulls say

Moderna demonstrates a robust financial trajectory, projecting product sales growth from $1.73 billion in 2025 to $2.15 billion in 2026, signifying its expanding market presence and operational capabilities. The recent $1.5 billion debt deal enhances the company's balance sheet and provides increased flexibility to navigate uncertainties while pursuing future opportunities, further underpinning its financial stability. Additionally, improvements in manufacturing efficiency are expected to re-expand gross margins, which have rebounded from a low of 30% in 2023 back to 50% in 2025, reflecting effective management and a strong recovery in profitability.

Bears say

Moderna's financial outlook has weakened significantly due to declining COVID vaccine sales, which dropped to $6.7 billion in 2023 from $18 billion in 2022, leading to reduced revenue guidance for 2025. The company's growth potential is further constrained by competitive pressures in the RSV vaccine market and slow progress in its broader pipeline beyond respiratory vaccines. As a result of these challenges, the valuation for COVID-related vaccines has also been revised downward from $11.70 billion to $10.50 billion, reflecting the decreasing importance of COVID sales amidst a transitioning pandemic landscape.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 8% recommend Buy, 67% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.